All sectors · Built to order
Life sciences due diligence and custom research for radiopharma, ADC, cell and gene therapy, CDMO and CRO
Investment and partner due diligence, deals and capital flows, competitor assessments, market entry by country, or any question the analyses above do not cover.
What you receive
- A written report that answers the questions agreed at scoping, with a clear verdict on each
- The read from the leaders running these businesses, gathered through our search work and attributed by role
- A data workbook with the underlying tables, so your team can filter, check and reuse the work
- A source register with the source and date behind each key fact
When the question in front of you is not one of the analyses above. Tell us the decision, the deadline and what you already know, and we scope the work to answer it.
Every answer draws on ProGen's proprietary intelligence base across radiopharma, ADC, cell and gene therapy, CDMO and CRO, and on the leaders our search practice speaks with every week.
Who commissions it
- Investors before an investment committee
- Corporate development teams before a licence, partnership or acquisition
- Strategy teams entering a modality or a country
- Leadership teams preparing a board decision
The questions it answers
- Investment due diligence: is the operating plan behind a company or programme deliverable?
- Partner due diligence: can a supplier, CDMO or CRO deliver what it is being chosen for?
- Deals and capital flows: who is buying, licensing and funding what, and on what terms?
- Competitor assessments: who else is building the same thing, how far along and with which partners?
- Market entry by country: suppliers, regulators, sites, partners and the people to hire
What you are buying access to
A proprietary intelligence base
Producers, facilities, pipelines, transactions, compensation and dated market signals across radiopharma, ADC, cell and gene therapy, CDMO and CRO, built and maintained by ProGen.
Access to the people who run it
Our executive search work puts us in conversation with the leaders of these businesses every week. Their read on the market goes into your answer.
Built around your decision
Scoped to the call in front of you: an investment, a partner, a supplier or a market. Every key fact sourced and dated.
How it works
Tell us your question
Choose an analysis below or describe your own. The more specific the decision, the sharper the scope.
Scope and quotation within one business day
We reply with the questions we will answer, what is in and out of scope, the timeline and a fixed quotation.
Your answer, built to stand up
A written report with a clear verdict, the read from the leaders in the space, a data workbook and a source register.
Request this analysis
Tell us the decision and the questions behind it. Within one business day you have the scope, the timeline and a fixed quotation.
Other analyses
- The Isotope Production MapEvery medical isotope producer, mapped by route and capacity. Refreshed quarterly.
- Ac-225 Supply and Demand OutlookWhen does Ac-225 stop being scarce, and who wins when it does?
- Isotope Supply Security AssessmentOne reactor, one target, one supplier. How exposed is your programme?
